BioSpace News Archive

Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) (“Dermata” or the “Company”), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.

Dr. Jaime Schwartz MD, FACS, a distinguished board-certified plastic surgeon and world-renowned specialist in Lipedema, is pioneering a transformative approach to treating this often misunderstood and underdiagnosed fat disorder.

Surface Oncology, Inc. announced that both Institutional Shareholder Services and Glass, Lewis & Co. have recommended Surface stockholders vote “FOR” the adoption of Surface’s merger agreement with Coherus BioSciences, Inc.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in September. Kyle Gano, Chief Business Development and Strategy Officer, and Todd Tushla, Vice President of Investor Relations, will present at the 2023 Wells Fargo Healthcare Conference at 3:45 p.m. Eastern Time on Thursday, September 7, 2023 in Boston.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will participate in three upcoming investor conferences in September.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023, at 10:15 a.m. ET.